Efficacy of azilsartan medoxomil with chlorthalidone in hypertension.
Author(s): Baker WL(1), Nigro SC, White WB.
Affiliation(s): Author information:
(1)University of Connecticut, School of Pharmacy, Storrs, CT, USA.
Publication date & source: 2014, Expert Rev Cardiovasc Ther. , 12(7):791-8
Azilsartan medoxomil (AZL) is the most recently approved angiotensin receptor
blocker (ARB) for treating patients with hypertension. A fixed-dose combination
product with AZL and the thiazide-like diuretic chlorthalidone (CLD) is now
available to treat individuals who require additional blood pressure lowering.
For this review, a literature search was conducted using MEDLINE and the keywords
and MeSH terms azilsartan, azilsartan medoxomil, chlorthalidone, thiazide, blood
pressure and hypertension. References for retrieved articles were also scanned
for relevant citations. No language restrictions were used. AZL is structurally
related to candesartan and has been shown to provide more potent angiotensin
receptor antagonism versus other ARBs. CLD is a thiazide-like diuretic with a
longer half-life and greater blood pressure lowering efficacy than
hydrochlorothiazide. The combination of AZL plus CLD has superior efficacy to
other ARBs alone or in combination with hydrochlorothiazide based on extensive
evaluation in clinical trials. This superior efficacy is not offset by a large
imbalance in clinically important adverse events.
|